Background: Control of cytosolic calcium plays a key role in airway myocyte function. Changes in intracellular Ca 2+ stores can modulate contractile responses, modulate proliferation and regulate synthetic activity. Influx of Ca 2+ in non excitable smooth muscle is believed to be predominantly through store operated channels (SOC) or receptor operated channels (ROC). Whereas agonists can activate both SOC and ROC in a range of smooth muscle types, the specific trigger for SOC activation is depletion of the sarcoplasmic reticulum Ca 2+ stores. The mechanism underlying SOC activation following depletion of intracellular Ca 2+ stores in smooth muscle has not been identified.
Background
Control of intracellular calcium is critical to regulation of smooth muscle function in many tissues. The relative contribution of SOC to the control of intracellular Ca 2+ varies between different types of smooth muscle, with SOC being particularly prominent in airway myocytes. The contractile/relaxant state of the airway myocyte is a key determinant of airway calibre thus contributing to bronchoconstriction in diseases such as asthma. Previous studies have demonstrated that the contractile response of airway myocytes is dependent initially upon release of intracellular Ca 2+ from the sarcoplasmic reticulum (reviewed in [1] ) but that sustained contraction is dependent upon influx from extracellular sources. Two mechanisms have been proposed to account for this influx in airway myocytes involving either activation of SOC or ROC. In contrast to vascular smooth muscle, L type voltage dependent calcium channels (VDCCs) appear to play a negligible role in control of Ca 2+ entry [2] .
In previous work we have demonstrated the expression of a number of TRP homologues including TRPC1, 3, 4 and 6 in cultured human airway myocytes and lung tissue and have suggested that TRPC6 may play an important role (probably together with other TRPC homologues including TRPC3 [3] ) in contributing to agonist induced ROC activity [4] .
SOC activation in many cell types including smooth muscle is known to involve depletion of the intracellular sarcoplasmic reticulum Ca 2+ stores. Contractile agonists such as acetylcholine, histamine and bradykinin may vary in their ability to differentially activate ROC or SOC although all agonists are known to induce activation of phospholipase C with consequent IP 3 mediated Ca 2+ release from the intracellular stores. The mechanism underlying signalling for subsequent Ca 2+ influx in response to store depletion, and hence refilling of the sarcoplasmic reticulum Ca 2+ stores, remains unknown. In the current study we have set out to define the signals for SOC activation in human airway myocytes following both store depletion and agonist activation by spasmogens.
Using RNA interference techniques STIM (stromal interaction molecule) 1 has been shown to play a role in SOC induced calcium entry in Drosophilia S2 cells, Jurkat T cells [5] and Hela cells [6] with the latter study also implicating a role for STIM2. In particular, STIM1 appears to be a major activator of calcium release activated calcium channels (I CRAC ) in T lymphocytes via a mechanism which has been proposed to involve translocation of STIM1 from endoplasmic reticulum like sites to the cell membrane [7] . We therefore hypothesised that homologues of STIM may play a role in SOC activation in smooth muscle. To address this hypothesis we used specific siRNA sequences to suppress both STIM1 and STIM2.
Methods

Cells
Human bronchial tissue was obtained from patients without a history of asthma. Human airway smooth muscle (HASM) cells were isolated and cultured as previously described [8] . Ethical approval for these studies was obtained from the Nottingham local ethical research committee. All subjects from whom tissue was obtained gave written consent. Primary human bronchial epithelial cells were obtained from Cambrex Bioscience (MD, USA) and grown in accordance with suppliers protocols. Cells at passage 4 were differentiated at an air-liquid interface on polyester tissue culture inserts (Corning, Costar) as described in a previous published method [9] .
Transfection of siRNAs siRNAs, including the scrambled siRNA control were purchased from Ambion (Huntingdon, Cambridge, UK). STIM1 siRNA (AAGGGAAGACCTCAATTACCA) was predesigned from Ambion, STIM2 siRNA (AACTGAGAAG-CAGTTGGTCTG) designed by Roos and colleagues [5] . Cells were transfected with siRNA (1-50 nM) in serum free medium over a period of 6 h, the medium was then aspirated and replaced with serum containing medium for a further period of 42 h. The transfection reagent used was Lipofectamine 2000 (Invitrogen, Paisley, UK) at a final concentration of 2 µl/ml.
Total RNA extraction and reverse transcriptase PCR Total RNA was isolated from pelleted cells using the RNeasy mini kit (Qiagen, West Sussex, UK) as per manufacturers' instructions. To examine for STIM1 and STIM2 expression, RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) and random hexamers (Invitrogen). PCR was performed using specific primers against STIM1 (Forward; AGGCAGTCCGTAACATCCAC, Reverse; CTTCAGTCCGTAACATCCAC) and STIM2 (Forward; TCCCTGCATGTCACTGAGTC, Reverse; GGGAAGT-GTCGTTCCTTTGA). Cycling was performed 35 times; 94°C, followed by 55°C (annealing temperature), then 72°C (all for 90 seconds) followed by 10 mins at 72°C. PCR products were visualized by ethidium bromide staining and confirmed by direct sequencing.
Real-Time PCR (Taqman)
siRNA targeted mRNA knockdown was measured using real time, quantitative PCR (Taqman). Gene specific primers and probes against STIM1 and STIM2 were designed using Primer Express™ software (Applied Biosystems, Foster City, CA) and using 18s RNA as the reference gene (Applied Biosystems). All probes were MGB probes, labeled with a 5'-reporter dye FAM and a non fluorescent quencher. Each sample was run in duplicate and mRNA knockdown was measured from mRNA obtained from 3 separate experiments. The relative expression of the target gene was calculated using the comparative method (2 -∆∆Ct ) [10] . Cells were then washed with Hanks' balanced saline solution containing 10 mM Hepes, 2.5 mM probenecid, 0.1 mM CaCl 2 and 1 mM MgCl 2 . The fluorescence was continuously recorded at wavelengths of 485 nm excitation and 520 nm emission using a Flexstation (Molecular Devices, Wokingham, UK). Cells were treated with 10 µM cyclopiazonic acid (final concentration) for 4 minutes followed by the addition of 1.9 mM CaCl 2 (2 mM final concentration). For agonist induced Ca 2+ responses, cells were stimulated with bradykinin (1 µM) or histamine (100 µM final concentration) for 4 minutes in 0.1 mM CaCl 2 buffer followed by the addition of 1.9 mM CaCl 2 . Data are presented as changes in fluorescence intensity (FI) compared with the baseline, the area under the curve was used as an estimation of changes in [Ca 2+ ] i .
Patch-clamp electrophysiology
The conventional whole-cell patch-clamp technique [11] was employed to record store operated inward currents in single HASM cells with an EPC-10 double amplifier and Patchmaster version 2.10 software (HEKA, Lambrecht, Germany). The compositions of the internal and external solutions are as follows; Standard Internal Solution; 110 mM Cs-methanesulfonate, 25 mM CsCl, 2 mM MgCl 2 , 10 mM EGTA, 30 mM HEPES, 3.62 mM CaCl 2 . External Solution: 140 mM NaCl, 5 mM CsCl, 1 mM MgCl 2 , 10 mM DGlucose, 10 mM HEPES, CaCl 2 (as indicated). K + was replaced by Cs + in both external and internal solutions to block K + currents and Cl -was replaced by an equal molar concentration of methanesulfonate to minimize Cl -currents. Nifedipine (5 µM) was included in the external solution. Pipettes were drawn from borosilicate glass and had resistances of 5-8 MΩ when filled with internal solution. HASM cells were placed directly into the cell chamber, allowed to settle and then were continuously perfused with external solution at a constant speed of 6 ml/min. Experimental drugs were delivered through a puffer pipette positioned 50 µm around the cells. Cells were held at a membrane potential of -60 mV and currentvoltage relationships were analysed every 5s from voltage ramps from -100 to +100 mV at a rate of 0.5 Vs -1 . Currents were filtered at 1 kHz and sampled at 4 KHz. Individual cell current densities were calculated by dividing peak current amplitude at maximum activation of inward current (at -100 mV) by cell capacitance.
Immunostaining
HASMs grown on coverslips, transfected with either 20 nM scrambled siRNA or 20 nM STIM1 siRNA were fixed with 4% formaldehyde. Cells were permeabilized (0.5% TritonX-100) and blocked with 20% goat serum in PBS for 20 min. Cells were incubated with primary antibody (mouse, anti-human STIM1 mAb (1:100) (BD Biosciences, Pharmingen) overnight at 4°C followed by labeling with Alexa fluor 488 (Molecular probes). Cells were visualized on a Zeiss LS 510 confocal microscope (Hertfordshire, UK).
Statistical analysis
Averaged data are presented as mean ± sem. Where appropriate, statistical significance was assessed by unpaired Students T tests or one-way ANOVA followed by the Dunnets test for multiple group comparisons. Data were considered significant at *P < 0.05 or **P < 0.01.
Results and discussion
Initially we assessed the expression of the two known human homologues STIM1 and STIM2 in cells relevant to airway function (figure 1a). Both STIM1 and STIM2 are highly expressed in primary cultures of airway myocytes and also in bronchial epithelial cells. We therefore utilised specific siRNA sequences to target and selectively suppress both STIM1 and STIM2 in order to investigate the role of these putative signals in SOC activation in airway myoctyes. siRNAs targeted at STIM1 and STIM2 produced dose dependent inhibition of the relevant target molecule without significant effects upon expression of either the other STIM homologue or 18sRNA (figure 1c &1d). Transfection of 20 nM siRNA specific for STIM1 or 2 resulted in robust decreases (>70%) of the relevant STIM mRNA. The ability to inhibit protein expression was evaluated by confocal microscopy for STIM1 alone (in view of functional data shown below) with marked inhibition of protein expression being evident following 48 hours exposure to the relevant siRNA (figure 1b).
We next evaluated the ability of siRNA targeted to STIM1 and STIM2 to inhibit SOC using a fluorescence assay utilising Fluo-4AM, designed to measure changes in intracellular free calcium concentration ([Ca 2+ ] i ) in monolayers of cultured human airway myocytes. SOC mediated Ca 2+ influx was induced by depletion of the sarcoplasmic reticulum Ca 2+ store using a combination of low external Ca 2+ (0.1 mM) and incubation with the SERCA inhibitor cyclopiazonic acid (CPA, 10 µM). Incubation of airway myocytes in low Ca 2+ in the presence of CPA resulted in an initial small rise in cytosolic Ca 2+ indicative of store depletion. Re-addition of extracellular Ca 2+ resulted in rapid influx into the cell through SOCs. siRNA targeted at STIM1 resulted in a dose-dependent reduction of SOC associated Ca 2+ influx ( figure 2a &2b) . Using 20 nM STIM1 siRNA, CPA dependant Ca 2+ influx was reduced by 60% compared to control cells. In contrast siRNA targeted at STIM2 had little effect upon SOC activation following store depletion (figure 2c &2d). Control cells initiated both CPA dependent and independent Ca 2+ influx (figure 2e) upon Ca 2+ re-addition. The mechanism of this basal Ca 2+ entry is unknown but previous studies in other cell types suggest that this passive Ca 2+ leak may not be due to SOC mediated influx [5] . In keeping with this, CPA independent/basal Ca 2+ influx was insensitive to siRNA mediated STIM1 suppression (data not shown).
We next used whole cell patch clamp electrophysiology approaches to confirm that siRNA targeted at STIM1 but not STIM2 is able to inhibit SOC activation. SOC currents were activated by reducing external Ca 2+ and application of 10 µM CPA. Current density was calculated by dividing peak current amplitude by cell capacitance; the average capacitance of the cells was 50.7 ± 4.1 pF (mean ± sem). SOC currents were induced by voltage ramps at a rate of 0.5 mV·ms -1 from a holding potential of -60 mV. Inward currents (SOC currents) measured at -100 mV were then compared. Changes in current density of SOC are illustrated in Figure 3 (a-c): preincubation with siRNA targeted to STIM1 almost completely abrogated SOC currents whereas siRNA targeted at STIM2 had no significant effect on SOC activation in these cells. Figure 3b shows the aver- SOC current (ie addition of 10 µM CPA in Ca 2+ free buffer). The STIM1 suppressed cells showed a reduced SOC inward current compared with cells treated with scrambled or STIM2 siRNA sequences. We also noticed a change in the reversal potential in the STIM1 suppressed cells towards a more negative potential: the significance of this is uncertain but similar findings on I CRAC currents have been reported using EF-hand mutants of STIM1 in RBL cells [12] . Results are expressed as % changes ± sem compared to control and represent averaged data from 4 separate experiments. Data are indicated as statistically significant with *P < 0.05 and **P < 0.01. CPA (10µ µ µ µM)
tor SKF96365 [2] . Previously however it has been impossible to disassociate the SOC and ROC components of the agonist induced Ca 2+ response to agonist. Following preincubation with siRNA targeted at STIM1 we observed a significant reduction in the magnitude of Ca 2+ influx induced by histamine ( figure 4d &4f) . These results suggest that under the conditions tested the STIM1 mediated SOC component may account for >50% of the Ca 2+ influx induced by histamine. We have previously shown histamine to induce a robust activation of phospholipase C in these cells which initiates IP 3 mediated Ca 2+ release from intracellular stores [8] . However there is evidence of agonist specific differences in the ability to activate SOC and ROC in airway myocytes: the ability of siRNA targeted against STIM1 to inhibit bradykinin induced Ca 2+ influx was limited (figure 4a and 4c) and markedly less than inhibition seen when histamine was used as the agonist.
This may suggest that stimulation of cognate receptors by these agonists vary in their ability to activate SOC or ROC (figure 4). The other possibility is that the difference may reflect variation in the extent of phospholipase C activation: the maximum inositol phospholipid hydrolysis response to bradykinin seen in these cells is around 3 times greater than the maximal response to histamine [8] .
The mechanism whereby STIM1 is able to activate SOC in airway myocytes remains to be determined. The STIM genes encode type 1 transmembrane proteins that can potentially form hetero or homo-oligomers via coiledcoiled interactions [13, 14] . The NH 2 terminus contains an EF-hand Ca 2+ binding motif which is thought to be responsible for the detection of Ca 2+ depletion in stores [6, 7, 12] . STIM1 is expressed in both plasma and intracellular membranes [13] and the EF hand is thought to be pA/pF ** located outside the cell or in the lumen of intracellular stores. It is conceivable that STIM proteins may interact (possibly through coiled coil domains) between the two membranes providing the vital link between intracellular stores and the plasma membrane [5] . Other models have been suggested including translocation of STIM1 from the endoplasmic reticulum to the plasma membrane [7] where STIM1 could directly activate SOC channels, or the involvement of STIM1 in the production of an unidentified Ca 2+ influx factor [15] .
The exact molecular identity of SOC in airway myocytes remains to be determined although potential candidates include a range of TRP homologues [3, 16, 17] . At present there are no specific tools to inhibit these channels directly and such approaches may be complicated by the formation of channels formed of heteromeric subunits.
Conclusion
Our data clearly implicates a role for STIM1 in SOC activation in airway myocytes providing for the first time molecular insight into this key signalling pathway in smooth muscle. Given the importance of control of intracellular Ca 2+ to airway smooth muscle contraction STIM1 may provide a potential therapeutic target for diseases characterised by increased smooth muscle contractility such as asthma. However, one note of caution must be added in that STIM1 was initially identified as a candidate tumour suppressor gene [18] and the consequences therefore of long term inhibition of STIM1 expression need to be explored further.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
Samantha Peel performed the mRNA expression and calcium studies, Bo Liu performed the electrophysiology and Ian P Hall wrote the paper. All authors were involved in the design of the studies, discussion of the results and preparation of the final manuscript.
